Tags

Type your tag names separated by a space and hit enter

Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party.
Am J Hematol. 2008 Sep; 83(9):702-7.AJ

Abstract

To identify the outcomes of prognostic factors of solitary plasmacytoma mainly treated with local radiotherapy (RT). The data were collected from 80 patients with solitary plasmacytoma (SP). Forty patients (50.0%) received radiotherapy (RT) alone while 38 of them (47.5%) were treated with surgery (S) and RT. The median radiation dose was 46 Gy (range 30-64). The median follow up was 2.41 years (range 0.33-12.33). Ten-year overall survival (OS) and local relapse-free survival (LRFS) were 73% and 94%, respectively. The median progression-free survival (PFS) and multiple myeloma-free survival (MMFS) were 3.5 years and 4.8 years, respectively. On multivariate analyses, the favorable factors were radiotherapy dose of > or =50 Gy and RT + S for PFS and younger age for MMFS. For the patients with medullary plasmacytoma, the favorable factor was younger age for MMFS. RT at > or =50 Gy and RT + S may be favorable prognostic factors on PFS. Younger patients, especially with head-neck lesion and without pre-RT macroscopic tumor, seem to have the best outcome when treated with RT +/- S. Progression to MM remains as the main problem especially for older patients.

Authors+Show Affiliations

Department of Radiation Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey. sevilkilciksiz@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

18543343

Citation

Kilciksiz, Sevil, et al. "Clinical and Prognostic Features of Plasmacytomas: a Multicenter Study of Turkish Oncology Group-Sarcoma Working Party." American Journal of Hematology, vol. 83, no. 9, 2008, pp. 702-7.
Kilciksiz S, Celik OK, Pak Y, et al. Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party. Am J Hematol. 2008;83(9):702-7.
Kilciksiz, S., Celik, O. K., Pak, Y., Demiral, A. N., Pehlivan, M., Orhan, O., Tokatli, F., Agaoglu, F., Zincircioglu, B., Atasoy, B. M., Ozseker, N., Yersal, O., Niang, U., & Haydaroglu, A. (2008). Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party. American Journal of Hematology, 83(9), 702-7. https://doi.org/10.1002/ajh.21211
Kilciksiz S, et al. Clinical and Prognostic Features of Plasmacytomas: a Multicenter Study of Turkish Oncology Group-Sarcoma Working Party. Am J Hematol. 2008;83(9):702-7. PubMed PMID: 18543343.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party. AU - Kilciksiz,Sevil, AU - Celik,Omur Karakoyun, AU - Pak,Yucel, AU - Demiral,Ayse Nur, AU - Pehlivan,Mustafa, AU - Orhan,Okan, AU - Tokatli,Fusun, AU - Agaoglu,Fulya, AU - Zincircioglu,Burhanedtin, AU - Atasoy,Beste Melek, AU - Ozseker,Naciye, AU - Yersal,Ozlem, AU - Niang,Umar, AU - Haydaroglu,Ayfer, AU - ,, PY - 2008/6/11/pubmed PY - 2008/9/19/medline PY - 2008/6/11/entrez SP - 702 EP - 7 JF - American journal of hematology JO - Am J Hematol VL - 83 IS - 9 N2 - To identify the outcomes of prognostic factors of solitary plasmacytoma mainly treated with local radiotherapy (RT). The data were collected from 80 patients with solitary plasmacytoma (SP). Forty patients (50.0%) received radiotherapy (RT) alone while 38 of them (47.5%) were treated with surgery (S) and RT. The median radiation dose was 46 Gy (range 30-64). The median follow up was 2.41 years (range 0.33-12.33). Ten-year overall survival (OS) and local relapse-free survival (LRFS) were 73% and 94%, respectively. The median progression-free survival (PFS) and multiple myeloma-free survival (MMFS) were 3.5 years and 4.8 years, respectively. On multivariate analyses, the favorable factors were radiotherapy dose of > or =50 Gy and RT + S for PFS and younger age for MMFS. For the patients with medullary plasmacytoma, the favorable factor was younger age for MMFS. RT at > or =50 Gy and RT + S may be favorable prognostic factors on PFS. Younger patients, especially with head-neck lesion and without pre-RT macroscopic tumor, seem to have the best outcome when treated with RT +/- S. Progression to MM remains as the main problem especially for older patients. SN - 1096-8652 UR - https://www.unboundmedicine.com/medline/citation/18543343/Clinical_and_prognostic_features_of_plasmacytomas:_a_multicenter_study_of_Turkish_Oncology_Group_Sarcoma_Working_Party_ L2 - https://doi.org/10.1002/ajh.21211 DB - PRIME DP - Unbound Medicine ER -